% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • martha.varias martha.varias Apr 25, 2013 9:58 AM Flag

    Influenza mutation

    There are many pharma companies with the ability to make a fast-track FDA approved vaccine for H7N9. There is a lot of competition for Inovio in this field.
    As H7N9 has indicated, new influenza subtypes appear more often and they are getting more dangerous.
    A vaccine for each new mutation needs some months, but even if it achieved in this short time, the virus can be mutated until then!

    What differs INOVIO from other companies, is the SynCon technology. SynCon universal influenza vaccines are focused to be capable of broad protection against existing and newly emergent unmatched strains.
    And very recently, INOVIO has proved, in a early stage though, at phase I, that they have achieved the same protective levels with the other vaccines.

    INOVIO is the company which has already focused and can resolve the major problem of influenza, the frequent mutations.
    This is not something the market can understand promptly, but beyond a few longs and a few shorters, there is a real market out there and INOVIO gets more known with Dr. Kim's interviews about influenza, with the ViE awards, and the publicity of SynCon influenza vaccines worldwide (pharmabiz India, Abu Dhabi topnews etc). Time will tell.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
7.18+0.12(+1.70%)Jul 27 4:00 PMEDT